Persistence and Adherence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis in US Commercial Claims Databases

被引：0
|
作者：
Engmann, N. [1 ]
Yang, E. [1 ]
Fiore, D. [1 ]
Pardo, G. [2 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P065
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [31] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
  • [32] Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis
    Zuckerman, Autumn D.
    DeClercq, Josh
    Simonson, Dana
    Zagel, Alicia L.
    Turco, Evan
    Banks, Aimee
    Wawrzyniak, Julie
    Rightmier, Elizabeth
    Blevins, Abbi
    Choi, Leena
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 75
  • [33] Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study
    Setayeshgar, Solmaz
    Kingwell, Elaine
    Zhu, Feng
    Zhang, Tingting
    Carruthers, Robert
    Marrie, Ruth Ann
    Evans, Charity
    Tremlett, Helen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 27 : 364 - 369
  • [34] Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
    Alosaimi, Fahad D.
    AlMulhem, Alaa
    AlShalan, Hanan
    Alqazlan, Mohammad
    Aldaif, Abdulgader
    Kowgier, Matthew
    Balasundaram, Janooshsheya
    Sockalingam, Sanjeev
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 513 - 518
  • [35] Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis
    Ozura, Ana
    Kovac, Lea
    Sega, Sasa
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S6 - S11
  • [36] Association between multiple sclerosis disease severity and adherence to disease-modifying therapies
    Burkhard, Adam
    Toliver, Joshua
    Rascati, Karen
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (07): : 915 - 923
  • [37] PRICE ANALYSIS OF MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES MARKETED IN THE US
    Bin Sawad, A.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    VALUE IN HEALTH, 2015, 18 (03) : A282 - A282
  • [38] Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US
    Krysko, Kristen M.
    Graves, Jennifer
    Rensel, Mary
    Weinstock-Guttman, Bianca
    Aaen, Gregory
    Benson, Leslie
    Chitnis, Tanuja
    Gorman, Mark
    Goyal, Manu
    Krupp, Lauren
    Lotze, Timothy
    Mar, Soe
    Rodriguez, Moses
    Rose, John
    Waltz, Michael
    Casper, T. Charles
    Waubant, Emmanuelle
    NEUROLOGY, 2018, 91 (19) : E1778 - E1787
  • [39] Comparison of adherence and persistence in patients initiating disease-modifying therapy for multiple sclerosis
    Meletiche, D.
    Shea, T.
    Wood, F.
    Shim, B.
    Becker, E.
    Bennett, R.
    AL-Sabbagh, A.
    JOURNAL OF NEUROLOGY, 2008, 255 : 79 - 79
  • [40] The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
    Pardo, Gabriel
    Pineda, Elmor D.
    Ng, Carmen D.
    Sheinson, Daniel
    Bonine, Nicole G.
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2022, 9 (01): : 111 - 116
12345